CASTLEFORD, England, April 19, 2010 /PRNewswire/ -- Teva UK Limited has welcomed the Department of Health's (DH) consultation on a Strategy for Services for Chronic Obstructive Pulmonary Disease (COPD).

As well as outlining a strategy for COPD services, the document also incorporates a strategy for asthma management.

Says Robyn Hughes, Director for Primary Secondary Care at Teva: Teva wholeheartedly supports the DH proposed strategy for COPD. The strategy seeks to put patient health at the centre by enabling patients to manage their condition themselves, and we believe this is key to its successful implementation.

Adds Robyn: We know it's important that patients understand the importance of lung health and risk factors, and these proposals seek to address the current situation where we have an estimated 2 million undiagnosed UK patients with COPD.1

The report also highlights issues around patients with asthma, and the importance of patient inhaler technique and of taking preventer medicine on a daily basis.1

The aim of the DH strategy is to ensure that COPD and asthma services are effective, give the patient control of their condition, and provide good value for money for taxpayers. The consultation runs until the end of April 2010.

Teva's sales of respiratory products such as inhalers make it the second largest pharmaceutical company in the UK market by number of respiratory products sold.

To find out more about Teva, visit


1. 1/4/2010

Notes to editors:

Teva UK Limited is one of the UK's leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. Measured by the volume of boxes supplied, it is the biggest single medicines supplier to the NHS. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company and has a number of respiratory products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.

For media enquiries, telephone the Teva Communications team on +44(0)1977-628500, or email


CONTACT: For media enquiries, telephone the Teva Communications team on+44(0)1977-628500, or email